Chitra Viswanathan MD, Presenter: Nothing to Disclose

Raghunandan Vikram MBBS,FRCR, Abstract Co-Author: Nothing to Disclose

Catherine Ellen Devine MD, Abstract Co-Author: Nothing to Disclose

Aparna Balachandran MD, Abstract Co-Author: Nothing to Disclose

Yulia Bronstein MD, Abstract Co-Author: Nothing to Disclose

Priya Ranjit Bhosale MD, Abstract Co-Author: ACT Biotech

The goals of this exhibit are: To provide an evidence based review of the utility of PET-CT in managements of patients with gynecologic malignancies To highlight the pearls and pitfalls in interpretation of PET-CT To provide radiologic clues to distinguish benign physiologic uptake from malignant disease

Review the epidemiology and evidence-based use of PET CT in management of common and uncommon gynecological malignancies such as cervical, ovarian, endometrial, vulvar, and fallopian carcinomas Show general pitfalls in PET-CT imaging related to SUV, motion and instrumentation Discuss physiologic and benign causes of FDG uptake, such as corpus luteum cysts and reactive adenopathy Evaluate the cause and give illustrative examples of false negative uptake on PET-CT, such as mucinous tumors

After completion of this exhibit, the viewer will have reviewed various PET-CT pitfalls in gynecologic imaging. Knowledge of these pitfalls will allow accurate interpretation and enable the radiologist to impact clinical management in oncologic patients.

Viswanathan, C, Vikram, R, Devine, C, Balachandran, A, Bronstein, Y, Bhosale, P, F18-FDG PET-CT in Gynecologic Malignancies: Evidence, Pearls, and Pitfalls.  Radiological Society of North America 2011 Scientific Assembly and Annual Meeting, November 26 - December 2, 2011 ,Chicago IL. http://archive.rsna.org/2011/11015706.html